Boston, MASSACHUSETTS4 Active Studies

Waldenstrom Macroglobulinemia Clinical Trials in Boston, MASSACHUSETTS

Find 4 actively recruiting waldenstrom macroglobulinemia clinical trials in Boston, MASSACHUSETTS. Connect with local research sites and explore new treatment options.

4
Active Trials
4
Sponsors
153
Enrolling

Recruiting Waldenstrom Macroglobulinemia Studies in Boston

About Waldenstrom Macroglobulinemia Clinical Trials in Boston

Waldenstrom macroglobulinemia is a rare type of non-Hodgkin lymphoma where cancer cells produce large amounts of an abnormal protein called macroglobulin. It progresses slowly and may not require immediate treatment. Options include targeted therapy, chemotherapy, and plasmapheresis.

There are currently 4 waldenstrom macroglobulinemia clinical trials recruiting participants in Boston, MASSACHUSETTS. These studies are seeking a combined 153 participants. Research is being sponsored by Massachusetts General Hospital, Dana-Farber Cancer Institute, Shayna Sarosiek, MD and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Waldenstrom Macroglobulinemia Clinical Trials in Boston — FAQ

Are there waldenstrom macroglobulinemia clinical trials in Boston?

Yes, there are 4 waldenstrom macroglobulinemia clinical trials currently recruiting in Boston, MASSACHUSETTS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What waldenstrom macroglobulinemia treatments are being tested?

The 4 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for waldenstrom macroglobulinemia.

Data updated March 2, 2026 from ClinicalTrials.gov